RANI Rani Therapeutics Holdings, Inc
$0.81▼ -3.42%
Healthcare
Other
Volume 321.9K
Avg Volume (10D) 445.7K
Key Metrics & Fundamentals
Market Cap
$113.43M
P/E Ratio
–
Div Yield
–%
52W Range
0.45 - 3.87
% vs 50 MA
4.49%
% vs 200 MA
-21.01%
RSI-14
49.8
MACD Histogram
-0.0100
Beta (1Y vs SPY)
3.24
Free Cash Flow
-$9.06M
Gross Rev
$1.71M
Gross Profit
$1.71M
EBITDA
-$8.26M
COGS
–
Operating Exp
$10.54M
Operating Income
-$8.83M
EBIT
-$8.83M
Pretax Income
-$8.42M
Net Income
-$7.39M
EPS (Diluted)
-0.04
Price & Volume History
Loading chart…
Recent News
Rani Therapeutics to Participate in Upcoming September Conferences
GlobeNewswire · Sep 8, 2026 12:00 PM
3 Small Cap Biotech Stocks Trading At A Discount With Late Stage Clinical Catalysts
Simply Wall St. · Aug 28, 2026 4:44 AM
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline
MarketBeat · Aug 16, 2026 8:01 PM
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
GlobeNewswire · Aug 13, 2026 8:05 PM
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
GlobeNewswire · Aug 4, 2026 12:00 PM
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Jul 20, 2026 8:05 PM
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
GlobeNewswire · Jul 15, 2026 12:00 PM
Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
GlobeNewswire · Jul 9, 2026 8:05 PM
Rani Therapeutics Names Nicholas Maestas CFO
MT Newswires · Jun 29, 2026 12:55 PM
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
GlobeNewswire · Jun 29, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See RANI's money flow as a full page
Social Sentiment
No Reddit posts found for RANI.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.